Prevalence and Clinical Significance of Mammalian Target of Rapamycin Phosphorylation (p-mTOR) and Vascular Endothelial Growth Factor (VEGF) in Clear Cell Carcinoma of the Ovary

  • Khemapech, Nipon (Gynecologic Oncology Division, Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University) ;
  • Pitchaiprasert, Sunaree (Surin Hospital) ;
  • Triratanachat, Surang (Gynecologic Pathology and Cytology Division, Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University)
  • 발행 : 2012.12.31


Background: To determine the prevalence of mammalian target of rapamycin phosphorylation (p-mTOR) and vascular endothelial growth factor (VEGF) and any correlation with clinical characteristics and prognosis in ovarian clear cell carcinoma patients. Materials and Method: Seventy four paraffin-embedded specimens of such carcinomas frompatients who underwent surgery, received adjuvant chemotherapy and were followed up at King Chulalongkorn Memorial Hospital during January 2002 to December 2008 were stained with rabbit monoclonal IgG p-mTOR and rabbit polyclonal IgG VEGF using immunohistochemical methods. Medical records were reviewed and clinical variables were analysed. Results: The prevalence of positive p-mTOR in ovarian clear cell carcinoma was 87.9% and significantly higher in advance-stage than early-stage patients (100% versus 83.6%, P<0.05). Two-year disease free survival and 2-year overall survival in patients with positive p-mTOR expression were 60% and 69.2% with no differences from patients with negative p-mTOR expression (p>0.05). The prevalence of VEGF expression was 63.5% and significantly higher in chemo-sensitive than chemo-resistant patients (70.7% versus 37.5%, P<0.05). Two-year disease free survival and 2-year overall survival in patients with VEGF expression were 72.3% and 83% respectively which were significantly different from patients with negative VEGF expression (p<0.05). Conclusions: p-mTOR expression in ovarian clear cell carcinoma was significantly correlated with the stage of disease. VEGF expression was significantly correlated with chemosensitivity, and survival. Further studies of related targeted therapy might be promising.


p-mTOR;VEGF;ovarian clear cell carcinoma;immunohistochemistry


  1. Pectasides D, Pectasides E, Psyrri A, Economopoulos T (2006). Treatment issues in clear cell carcinoma of the ovary: A different entity? Oncologist, 11, 1089-94.
  2. Rowinsky EK (2004). Targeting the molecular target of rapamycin (mTOR). Curr Opin Oncol, 16, 564-75.
  3. Smolewski P (2006). Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway. Anticancer Drugs, 17, 487-94.
  4. Sonmezer M, Gungor M, Ensari A, Ortac F (2004). Prognostic significance of tumor angiogenesis in epithelial ovarian cancer: in association with transforming growth factor beta and vascular endothelial growth factor. Int J Gynecol Cancer, 14, 82-8.
  5. Springett GM, Bonham L, Hummer A, et al (2005). Lysophosphatidic acid acyltransferase-beta is a prognostic marker and therapeutic target in gynecologic malignancies. Cancer Res, 65, 9415-25.
  6. Sugiyama T, Kamura T, Kigawa J, et al (2000). Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer, 88, 2584-9.<2584::AID-CNCR22>3.0.CO;2-5
  7. Trinh XB, Tjalma WA, Vermeulen PB, et al (2009). The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer. Br J Cancer, 100, 971-8.
  8. Xing D, Orsulic S (2005). Modeling resistance to pathwaytargeted therapy in ovarian cancer. Cell Cycle, 4, 1004-6.
  9. Yagyu T, Tsuji Y, Haruta S, et al (2006). Activation of mammalian target of rapamycin in postmenopausal ovarian endometriosis. Int J Gynecol Cancer, 16, 1545-51.
  10. Yap TA, Carden CP, Kaye SB (2009). Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer, 9, 167-81.
  11. Zhang HY, Zhang PN, Sun H (2009). Aberration of the PI3K/ AKT/mTOR signaling in epithelial ovarian cancer and its implication in cisplatin-based chemotherapy. Eur J Obstet Gynecol Reprod Biol, 146, 81-6.
  12. Altomare DA, Wang HQ, Skele KL, et al (2004). AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene, 23, 5853-7.
  13. Behbakht K, Randall TC, Benjamin I, et al (1998). Clinical characteristics of clear cell carcinoma of the ovary. Gynecol Oncol, 70, 255-8.
  14. Behbakht K, Sill MW, Darcy KM, et al (2011). Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a gynecologic oncology group study. Gynecol Oncol, 123, 19-26.
  15. Chan S (2004).Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer, 91, 1420-4.
  16. Chon HS, Hu W, Kavanagh JJ (2006). Targeted therapies in gynecologic cancers. Curr Cancer Drug Targets, 6, 333-63.
  17. Hidalgo M, Rowinsky EK (2000). The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene, 19, 6680-6.
  18. Huang S, Houghton PJ (2003). Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol, 3, 371-7.
  19. Huynh H, Teo CC, Soo KC (2007). Bevacizumab and rapamycin inhibit tumor growth in peritoneal model of human ovarian cancer. Mol Cancer Ther, 6, 2959-66.
  20. Itamochi H, Kigawa J (2012). Clinical trials and future potential of targeted therapy for ovarian cancer. Int J Clin Oncol, 17, 430-40.
  21. Janus A, Robak T, Smolewski P (2005). The mammalian target of the rapamycin (mTOR) kinase pathway: its role in tumourigenesis and targeted antitumour therapy. Cell Mol Biol Lett, 10, 479-98.
  22. Mabuchi S, Kawase C, Altomare DA, et al (2009). mTOR Is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary. Clin Cancer Res, 15, 5404-13.
  23. Meric-Bernstam F, Mills GB (2004). Mammalian target of rapamycin. Semin Oncol, 31, 10-7.
  24. Mita MM, Mita A, Rowinsky EK (2003). The molecular target of rapamycin (mTOR) as a therapeutic target against cancer. Cancer Biol Ther, 2, 169-77.
  25. Miyazawa M, Yasuda M, Fujita M, et al (2009). Therapeutic strategy targeting the mTOR-HIF-1alpha-VEGF pathway in ovarian clear cell adenocarcinoma. Pathol Int, 59, 19-27.
  26. Nagaraja AK, Creighton CJ, Yu Z, et al (2010). A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer. Mol Endocrinol, 24, 447-63.
  27. Noske A, Lindenberg JL, Darb-Esfahani S, et al (2008). Activation of mTOR in a subgroup of ovarian carcinomas: correlation with p-eIF-4E and prognosis. Oncol Rep, 20, 1409-17.
  28. Jemal A, Siegel R, Ward E, et al (2009).Cancer statistics, 2009. CA Cancer J Clin; published online. doi:10.3322/ caac.20006. Available from statfacts/html/ovary.html#ref09 and search?q=serous+ovary+2009.

피인용 문헌

  1. Effects of Rapamycin on Cell Apoptosis in MCF-7 Human Breast Cancer Cells vol.15, pp.24, 2015,
  2. Diagnostic and Therapeutic Implications of the Vascular Endothelial Growth Factor Family in Cancer vol.16, pp.5, 2015,